Table 1

Clinical characteristics of super-responders and non-responders to zonisamide in this study

VariablesResponsivenessP value (SR vs NR)*
SR (n=23)NR (n=25)
Female sex (%)11/23 (47.8%)13/25 (52.0%)
Age (mean±SD)63.3±6.765.1±6.10.48
BMI (mean±SD)24.4±2.921.8±3.30.05
Onset age of PD (year, mean±SD)57.4±7.855.9±8.70.39
Years with PD (year, mean±SD)5.9±2.88.0±5.20.40
Onset age of ‘wearing-off’ (year, mean±SD)61.1±8.160.6±8.40.28
Years with ‘wearing-off’ (year, mean±SD)2.2±3.12.3±3.30.36
MMSE (mean±SD)27.8±2.628.17±2.10.35
Modified Hoehn and Yahr score (ON) (mean±SD)2.5±0.32.1±0.80.16
Modified Hoehn and Yahr score (OFF) (mean±SD)3.3±0.63.3±0.70.44
Dose of levodopa (mg/day, mean±SD)350.0±120.2416.7±181.30.48
LEDD† (mg/day, mean±SD)491.8±163.5497.1±203.50.20
Dose of MAO-B inhibitors (mg/day, mean±SD)4.2±1.45.0±2.00.33
No of concomitant drugs (mean±SD)2.8±0.83.0±1.50.07
Plasma concentration of zonisamide at week 4 (µg/mL)1.1±0.51.1±0.30.16
Total UPDRS part III total score at week 12 (mean±SD)13.7±10.018.3±9.25.0×10−3
Total UPDRS part III total score at baseline (mean±SD)21.4±9.414.3±9.80.050
Changes of UPDRS III from baseline (mean±SD)−7.7±3.04.0±7.02.8×10−10
Average ‘off’ time at week 12‡ (mean±SD)4.2±2.27.3±2.81.6×10−5
Average ‘off’ time at baseline (mean±SD)7.0±1.75.8±2.40.018
Changes of ‘off’ time from baseline (mean±SD)−2.8±1.61.5±1.42.6×10−15
  • *P values were determined by using two-tailed unpaired t-test with equal variance.

  • †Conversion factor for LEDD: bromocriptine mesilate, ×10; cabergoline, ×70; pergolide mesilate, ×100; pramipexole hydrochloride hydrate, ×60; ropinirole hydrochloride, ×16.67; talipexole hydrochloride, ×60.

  • ‡'Off’ time was calculated using patients' diary information for the last 7 days before each visit (excluding screening visit).

  • BMI, body mass index; LEDD, levodopa-equivalent daily dose; MAO-B, monoamine oxidase-B; MMSE, Mini–Mental State Examination; NR, non-responder; PD, Parkinson’s disease; SR, super-responder; UPDRS, Unified Parkinson’s Disease Rating Scale.